{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:25:20Z","timestamp":1793993120900,"version":"4.8.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T00:00:00Z","timestamp":1531094400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1038\/s41591-018-0089-4","type":"journal-article","created":{"date-parts":[[2018,7,6]],"date-time":"2018-07-06T09:38:07Z","timestamp":1530869887000},"page":"1108-1112","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":247,"title":["Verapamil and beta cell function in adults with recent-onset type 1 diabetes"],"prefix":"10.1038","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6711-071X","authenticated-orcid":false,"given":"Fernando","family":"Ovalle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Grimes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanlan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish J.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Truman B.","family":"Grayson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance A.","family":"Thielen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9026-9999","authenticated-orcid":false,"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anath","family":"Shalev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,9]]},"reference":[{"key":"89_CR1","doi-asserted-by":"publisher","first-page":"848","DOI":"10.2337\/db11-0955","volume":"61","author":"G Xu","year":"2012","unstructured":"Xu, G., Chen, J., Jing, G. & Shalev, A. Preventing beta-cell loss and diabetes with calcium channel blockers. Diabetes 61, 848\u2013856 (2012).","journal-title":"Diabetes"},{"key":"89_CR2","doi-asserted-by":"publisher","first-page":"476","DOI":"10.2337\/dc14-1952","volume":"38","author":"AK Davis","year":"2015","unstructured":"Davis, A. K. et al. Prevalence of detectable C-peptide according to age at diagnosis and duration of type 1 diabetes. Diabetes Care 38, 476\u2013481 (2015).","journal-title":"Diabetes Care"},{"key":"89_CR3","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s00125-009-1342-7","volume":"52","author":"EH Liu","year":"2009","unstructured":"Liu, E. H. et al. Pancreatic beta cell function persists in many patients with chronic type 1 diabetes, but is not dramatically improved by prolonged immunosuppression and euglycaemia from a beta cell allograft. Diabetologia 52, 1369\u20131380 (2009).","journal-title":"Diabetologia"},{"key":"89_CR4","doi-asserted-by":"crossref","unstructured":"The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial: a randomized, controlled trial. Ann. Intern. Med. 128, 517\u2013523 (1998).","DOI":"10.7326\/0003-4819-128-7-199804010-00001"},{"key":"89_CR5","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.1210\/en.2002-220564","volume":"143","author":"A Shalev","year":"2002","unstructured":"Shalev, A. et al. Oligonucleotide microarray analysis of intact human pancreatic islets: identification of glucose-responsive genes and a highly regulated TGFbeta signaling pathway. Endocrinology 143, 3695\u20133698 (2002).","journal-title":"Endocrinology"},{"key":"89_CR6","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1096\/fj.08-111690","volume":"22","author":"J Chen","year":"2008","unstructured":"Chen, J. et al. Thioredoxin-interacting protein deficiency induces Akt\/Bcl-xL signaling and pancreatic beta cell mass and protects against diabetes. FASEB J. 22, 3581\u20133594 (2008).","journal-title":"FASEB J."},{"key":"89_CR7","doi-asserted-by":"publisher","first-page":"938","DOI":"10.2337\/db07-0715","volume":"57","author":"J Chen","year":"2008","unstructured":"Chen, J., Saxena, G., Mungrue, I. N., Lusis, A. J. & Shalev, A. Thioredoxin-interacting protein: a critical link between glucose toxicity and beta cell apoptosis. Diabetes 57, 938\u2013944 (2008).","journal-title":"Diabetes"},{"key":"89_CR8","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1210\/en.2004-1378","volume":"146","author":"AH Minn","year":"2005","unstructured":"Minn, A. H., Hafele, C. & Shalev, A. Thioredoxin-interacting protein is stimulated by glucose through a carbohydrate response element and induces beta-cell apoptosis. Endocrinology 146, 2397\u20132405 (2005).","journal-title":"Endocrinology"},{"key":"89_CR9","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.bbrc.2005.08.161","volume":"336","author":"AH Minn","year":"2005","unstructured":"Minn, A. H. et al. Gene expression profiling in INS-1 cells overexpressing thioredoxin-interacting protein. Biochem. Biophys. Res. Commun. 336, 770\u2013778 (2005).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"89_CR10","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1152\/ajpendo.90944.2008","volume":"296","author":"J Chen","year":"2009","unstructured":"Chen, J., Cha-Molstad, H., Szabo, A. & Shalev, A. Diabetes induces and calcium channel blockers prevent cardiac expression of pro-apoptotic thioredoxin-interacting protein. Am. J. Physiol. Endocrinol. Metab. 296, 1133\u20131139 (2009).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"89_CR11","doi-asserted-by":"publisher","first-page":"936","DOI":"10.2337\/diab.37.7.936","volume":"37","author":"N Afzal","year":"1988","unstructured":"Afzal, N. et al. Beneficial effects of verapamil in diabetic cardiomyopathy. Diabetes 37, 936\u2013942 (1988).","journal-title":"Diabetes"},{"key":"89_CR12","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1172\/JCI11642","volume":"107","author":"RD Cohn","year":"2001","unstructured":"Cohn, R. D. et al. Prevention of cardiomyopathy in mouse models lacking the smooth muscle sarcoglycan-sarcospan complex. J. Clin. Invest. 107, R1\u2013R7 (2001).","journal-title":"J. Clin. Invest."},{"key":"89_CR13","doi-asserted-by":"crossref","unstructured":"Xu, G., Chen, J., Jing, G. & Shalev, A. Thioredoxin-interacting protein regulates insulin transcription through microRNA-204. Nat. Med. 19, 1141\u20131146 (2013).","DOI":"10.1038\/nm.3287"},{"key":"89_CR14","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2337\/db17-0506","volume":"67","author":"S Jo","year":"2018","unstructured":"Jo, S. et al. miR-204 controls glucagon-like peptide 1 receptor expression and agonist function. Diabetes 67, 256\u2013264 (2018).","journal-title":"Diabetes"},{"key":"89_CR15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/ni.1831","volume":"11","author":"R Zhou","year":"2010","unstructured":"Zhou, R., Tardivel, A., Thorens, B., Choi, I. & Tschopp, J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 11, 136\u2013140 (2010).","journal-title":"Nat. Immunol."},{"key":"89_CR16","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1210\/jc.2016-3778","volume":"102","author":"T Yin","year":"2017","unstructured":"Yin, T., Kuo, S. C., Chang, Y. Y., Chen, Y. T. & Wang, K. K. Verapamil use is associated with reduction of newly diagnosed diabetes mellitus. J. Clin. Endocrinol. Metab. 102, 2604\u20132610 (2017).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"89_CR17","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.amjcard.2006.04.030","volume":"98","author":"R Cooper-Dehoff","year":"2006","unstructured":"Cooper-Dehoff, R. et al. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am. J. Cardiol. 98, 890\u2013894 (2006).","journal-title":"Am. J. Cardiol."},{"key":"89_CR18","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.ahj.2005.05.024","volume":"151","author":"RM Cooper-DeHoff","year":"2006","unstructured":"Cooper-DeHoff, R. M. et al. Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients: findings from the International Verapamil SR\/Trandolapril Study (INVEST). Am. Heart J. 151, 1072\u20131079 (2006).","journal-title":"Am. Heart J."},{"key":"89_CR19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/BF00626359","volume":"41","author":"M Busch Sorensen","year":"1991","unstructured":"Busch Sorensen, M. et al. Influence of short term verapamil treatment on glucose metabolism in patients with non-insulin dependent diabetes mellitus. Eur. J. Clin. Pharmacol. 41, 401\u2013404 (1991).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"89_CR20","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.diabres.2016.01.021","volume":"115","author":"Y Khodneva","year":"2016","unstructured":"Khodneva, Y., Shalev, A., Frank, S. J., Carson, A. P. & Safford, M. M. Calcium channel blocker use is associated with lower fasting serum glucose among adults with diabetes from the REGARDS study. Diabetes Res. Clin. Pract. 115, 115\u2013121 (2016).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"89_CR21","doi-asserted-by":"publisher","first-page":"S74","DOI":"10.1089\/dia.2017.2507","volume":"19","author":"B Nambam","year":"2017","unstructured":"Nambam, B., Bratina, N. & Schatz, D. Immune interventions for type 1 diabetes mellitus. Diabetes Technol. & Ther. 19, S74\u2013S81 (2017).","journal-title":"Diabetes Technol. & Ther."},{"key":"89_CR22","unstructured":"Alhadj Ali, M.et al. Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes. Sci. Transl. Med. 9, eaaf7779 (2017)."},{"key":"89_CR23","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1056\/NEJMoa012864","volume":"346","author":"KC Herold","year":"2002","unstructured":"Herold, K. C. et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. New Engl. J. Med. 346, 1692\u20131698 (2002).","journal-title":"New Engl. J. Med."},{"key":"89_CR24","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.2337\/dc13-0327","volume":"37","author":"R Aronson","year":"2014","unstructured":"Aronson, R. et al. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care 37, 2746\u20132754 (2014).","journal-title":"Diabetes Care"},{"key":"89_CR25","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","volume":"361","author":"MD Pescovitz","year":"2009","unstructured":"Pescovitz, M. D. et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. New Engl. J. Med. 361, 2143\u20132152 (2009).","journal-title":"New Engl. J. Med."},{"key":"89_CR26","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nrendo.2015.8","volume":"11","author":"P Pozzilli","year":"2015","unstructured":"Pozzilli, P., Maddaloni, E. & Buzzetti, R. Combination immunotherapies for type 1 diabetes mellitus. Nat. Rev. Endocrinol. 11, 289\u2013297 (2015).","journal-title":"Nat. Rev. Endocrinol."},{"key":"89_CR27","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.2337\/db11-1538","volume":"61","author":"CJ Greenbaum","year":"2012","unstructured":"Greenbaum, C. J. et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 61, 2066\u20132073 (2012).","journal-title":"Diabetes"},{"key":"89_CR28","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.2337\/dc16-0360","volume":"39","author":"W Hao","year":"2016","unstructured":"Hao, W. et al. Fall in C-peptide during first 4 years from diagnosis of type 1 diabetes: variable relation to age, HbA1c, and insulin dose. Diabetes Care 39, 1664\u20131670 (2016).","journal-title":"Diabetes Care"},{"key":"89_CR29","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.2337\/dc07-2451","volume":"31","author":"CJ Greenbaum","year":"2008","unstructured":"Greenbaum, C. J. et al. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 31, 1966\u20131971 (2008).","journal-title":"Diabetes Care"},{"key":"89_CR30","doi-asserted-by":"publisher","first-page":"250","DOI":"10.2337\/diabetes.53.1.250","volume":"53","author":"JP Palmer","year":"2004","unstructured":"Palmer, J. P. et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 53, 250\u2013264 (2004).","journal-title":"Diabetes"},{"key":"89_CR31","doi-asserted-by":"publisher","first-page":"e26471","DOI":"10.1371\/journal.pone.0026471","volume":"6","author":"JM Lachin","year":"2011","unstructured":"Lachin, J. M. et al. Sample size requirements for studies of treatment effects on beta-cell function in newly diagnosed type 1 diabetes. PLoS One 6, e26471 (2011).","journal-title":"PLoS One"},{"key":"89_CR32","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/j.1752-8062.2011.00347.x","volume":"4","author":"CG Moore","year":"2011","unstructured":"Moore, C. G., Carter, R. E., Nietert, P. J. & Stewart, P. W. Recommendations for planning pilot studies in clinical and translational research. Clin. Transl. Sci. 4, 332\u2013337 (2011).","journal-title":"Clin. Transl. Sci."},{"key":"89_CR33","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1001\/jama.2015.15281","volume":"314","author":"P Li","year":"2015","unstructured":"Li, P., Stuart, E. A. & Allison, D. B. Multiple imputation: a flexible tool for handling missing data. JAMA 314, 1966\u20131967 (2015).","journal-title":"JAMA"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41591-018-0089-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-018-0089-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-018-0089-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:56:32Z","timestamp":1684605392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-018-0089-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,9]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["89"],"URL":"https:\/\/doi.org\/10.1038\/s41591-018-0089-4","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,9]]},"assertion":[{"value":"8 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}